Roche's lung cancer gamble flames out as TIGIT digits come up short in phase 3
Roche’s gamble on anti-TIGIT drug tiragolumab in small cell lung cancer (SCLC) has flamed out.
Source: fiercebiotech.com
Page 2 - Failed Trials News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Failed Trials. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Failed Trials Today - Breaking & Trending Today
Icosavax's COVID-19 shot fails to deliver in early data, spurring debate about 'fatal flaw' in platform
Early underwhelming data from Icosavax's COVID-19 vaccine has sent investors sprinting towards the exits, bringing into question whether the biotech's entire platform has a "fatal flaw."
Source: fiercebiotech.com
BridgeBio's 'baffling' heart disease drug fail 'de-intensifies' competition for Alnylam
BridgeBio's shot at entering a competitive market for a rare heart condition narrowed Monday after a "baffling" result in a phase 3 clinical trial where placebo patients bested those who received the treatment in a walk test.
Source: fiercebiotech.com
Dicerna narrows focus for kidney drug after mixed data, setting up head-to-head market battle with rival Alnylam
Dicerna is still paving a way forward for its troubled late-stage RNAi asset nedosiran as it looks to gun for an FDA approval in just one sub-type of a rare disease after ratcheting up another mixed bag of data.
Source: fiercebiotech.com
Atea and Roche's COVID-19 antiviral flunks phase 2, prompting switch that will delay pivotal data
Atea Pharmaceuticals and Roche have suffered a big blow to their bid to bring an oral antiviral for COVID-19 to market. A phase 2 trial of the candidate missed its primary endpoint, prompting Atea and Roche to consider changes that will delay data from a pivotal study by around one year.
Source: fiercebiotech.com